Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04178551 · ClinicalTrials.gov registry record · NA
Consortium to Disseminate and Understand Implementation of Opioid Use Disorder Treatment
A NA study of Opioid Medication Assisted Treatment, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
- 11
- Study locations
NCT04178551: Completed NA study of Opioid Medication Assisted Treatment, sponsored by VA Office of Research and Development.
NCT04178551 is a NA study of Opioid Medication Assisted Treatment that has completed, run by VA Office of Research and Development. The registered enrollment target is 63 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04178551, a NA study of Opioid Medication Assisted Treatment, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
- 11
- Study locations
Study Summary
Opioid use disorder (OUD) is a major cause of illness and death among Veterans for which effective treatment is a major priority of the Veterans Health Administration (VHA). Expanding access to alternatives to opioid medications for chronic pain management is also a leading priority. Effective medications for OUD (MOUD) are available, but their availability and use among Veterans varies across VHA. The aims of this study are to pull together the efforts of six individual pilot projects into a single project. The purpose of combining the projects is to maximize the value of the individual projects to VHA and to provide information to guide strategies to increase access and use of MOUD and alternative therapies for pain in VHA nationally. The researchers leading the individual projects will make use of their partnerships with Veterans Integrated Service Network (VISN) leaders in order to develop a combined effort toward increased dissemination and use of MOUD that spans 9 VISNs and 63 sites.
Primary Outcome
Data will be extracted from patients electronic health records and reported at the site level. The denominator for this measure is the number of patients within participating sites eligible to receive MOUD at the site during the target period. This outcome will be compared to pre-implementation.
Conditions Studied
Interventions
- OTHER Implementation Facilitation
Study Locations (11)
Alabama
- Birmingham VA Medical Center, Birmingham, AL - Birmingham
California
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA - West Los Angeles
Colorado
- Rocky Mountain Regional VA Medical Center, Aurora, CO - Aurora
Connecticut
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT - West Haven
Idaho
- Boise VA Medical Center, Boise, ID - Boise
Iowa
- Iowa City VA Health Care System, Iowa City, IA - Iowa City
Maine
- Maine VA Medical Center, Augusta, ME - Augusta
Massachusetts
- VA Central Western Massachusetts Healthcare System, Leeds, MA - Leeds
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2022-09-30 |
| Phase | NA |
What the finished NCT04178551 record still lists
NCT04178551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Opioid Medication Assisted Treatment appearing as the primary indexed condition, and to 1 intervention - of which Implementation Facilitation is the first listed.
NCT04178551 lists 11 locations in 11 states (Alabama, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT04178551 about?
NCT04178551 is a clinical study titled "Consortium to Disseminate and Understand Implementation of Opioid Use Disorder Treatment". Opioid use disorder (OUD) is a major cause of illness and death among Veterans for which effective treatment is a major priority of the Veterans Health Administration (VHA). Expanding access to alternatives to opioid medications for chronic pain management is also a leading priority. Effective medic...
What is the current status of trial NCT04178551?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2019-10-01. Estimated completion is 2022-09-30.
What conditions does trial NCT04178551 study?
This clinical trial studies the following conditions: Opioid Medication Assisted Treatment.
What interventions are being tested in trial NCT04178551?
The interventions under investigation include: Implementation Facilitation (OTHER).
Who is sponsoring clinical trial NCT04178551?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04178551 being conducted?
This trial has 11 study locations across Alabama, California, Colorado, Connecticut, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Medication Assisted Treatment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04178551's enrollment target sits among peer trials
63 1157th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI